These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 34450259)

  • 1. KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy.
    Scalera S; Mazzotta M; Corleone G; Sperati F; Terrenato I; Krasniqi E; Pizzuti L; Barba M; Vici P; Gallo E; Buglioni S; Visca P; Pescarmona E; Marinelli D; De Nicola F; Ciuffreda L; Goeman F; Fanciulli M; Giusti R; Vecchione A; De Maria R; Cappuzzo F; Marchetti P; Ciliberto G; Maugeri-Saccà M
    J Thorac Oncol; 2021 Dec; 16(12):2065-2077. PubMed ID: 34450259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden.
    Marinelli D; Mazzotta M; Scalera S; Terrenato I; Sperati F; D'Ambrosio L; Pallocca M; Corleone G; Krasniqi E; Pizzuti L; Barba M; Carpano S; Vici P; Filetti M; Giusti R; Vecchione A; Occhipinti M; Gelibter A; Botticelli A; De Nicola F; Ciuffreda L; Goeman F; Gallo E; Visca P; Pescarmona E; Fanciulli M; De Maria R; Marchetti P; Ciliberto G; Maugeri-Saccà M
    Ann Oncol; 2020 Dec; 31(12):1746-1754. PubMed ID: 32866624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.
    Ricciuti B; Arbour KC; Lin JJ; Vajdi A; Vokes N; Hong L; Zhang J; Tolstorukov MY; Li YY; Spurr LF; Cherniack AD; Recondo G; Lamberti G; Wang X; Venkatraman D; Alessi JV; Vaz VR; Rizvi H; Egger J; Plodkowski AJ; Khosrowjerdi S; Digumarthy S; Park H; Vaz N; Nishino M; Sholl LM; Barbie D; Altan M; Heymach JV; Skoulidis F; Gainor JF; Hellmann MD; Awad MM
    J Thorac Oncol; 2022 Mar; 17(3):399-410. PubMed ID: 34740862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma.
    Goeman F; De Nicola F; Scalera S; Sperati F; Gallo E; Ciuffreda L; Pallocca M; Pizzuti L; Krasniqi E; Barchiesi G; Vici P; Barba M; Buglioni S; Casini B; Visca P; Pescarmona E; Mazzotta M; De Maria R; Fanciulli M; Ciliberto G; Maugeri-Saccà M
    J Thorac Oncol; 2019 Nov; 14(11):1924-1934. PubMed ID: 31323387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma.
    Scalera S; Ricciuti B; Mazzotta M; Calonaci N; Alessi JV; Cipriani L; Bon G; Messina B; Lamberti G; Di Federico A; Pecci F; Milite S; Krasniqi E; Barba M; Vici P; Vecchione A; De Nicola F; Ciuffreda L; Goeman F; Fanciulli M; Buglioni S; Pescarmona E; Sharma B; Felt KD; Lindsay J; Rodig SJ; De Maria R; Caravagna G; Cappuzzo F; Ciliberto G; Awad MM; Maugeri-Saccà M
    Ann Oncol; 2023 Mar; 34(3):275-288. PubMed ID: 36526124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma.
    Boiarsky D; Lydon CA; Chambers ES; Sholl LM; Nishino M; Skoulidis F; Heymach JV; Luo J; Awad MA; Janne PA; Van Allen EM; Barbie DA; Vokes NI
    Ann Oncol; 2023 Jul; 34(7):589-604. PubMed ID: 37121400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KEAP1 and TP53 (Co)mutation in Lung Adenocarcinoma: Another Bullet for Immunotherapy?
    Pelosi G
    J Thorac Oncol; 2021 Dec; 16(12):1979-1983. PubMed ID: 34809800
    [No Abstract]   [Full Text] [Related]  

  • 8. KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance.
    Zavitsanou AM; Pillai R; Hao Y; Wu WL; Bartnicki E; Karakousi T; Rajalingam S; Herrera A; Karatza A; Rashidfarrokhi A; Solis S; Ciampricotti M; Yeaton AH; Ivanova E; Wohlhieter CA; Buus TB; Hayashi M; Karadal-Ferrena B; Pass HI; Poirier JT; Rudin CM; Wong KK; Moreira AL; Khanna KM; Tsirigos A; Papagiannakopoulos T; Koralov SB
    Cell Rep; 2023 Nov; 42(11):113295. PubMed ID: 37889752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma.
    Vokes NI; Chambers E; Nguyen T; Coolidge A; Lydon CA; Le X; Sholl L; Heymach JV; Nishino M; Van Allen EM; Jänne PA
    J Thorac Oncol; 2022 Jun; 17(6):779-792. PubMed ID: 35331964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma.
    Liang Y; Maeda O; Kondo C; Nishida K; Ando Y
    PLoS One; 2024; 19(7):e0307580. PubMed ID: 39037971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Redox
    Wei XW; Lu C; Zhang YC; Fan X; Xu CR; Chen ZH; Wang F; Yang XR; Deng JY; Yang MY; Gou Q; Mei SQ; Luo WC; Zhong RW; Zhong WZ; Yang JJ; Zhang XC; Tu HY; Wu YL; Zhou Q
    Oncoimmunology; 2024; 13(1):2340154. PubMed ID: 38601319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lung adenocarcinoma patients with KEAP1 mutation harboring low immune cell infiltration and low activity of immune environment.
    Cheng W; Xu B; Zhang H; Fang S
    Thorac Cancer; 2021 Sep; 12(18):2458-2467. PubMed ID: 34328274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
    Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
    JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NFE2L2/KEAP1 Mutations Correlate with Higher Tumor Mutational Burden Value/PD-L1 Expression and Potentiate Improved Clinical Outcome with Immunotherapy.
    Xu X; Yang Y; Liu X; Cao N; Zhang P; Zhao S; Chen D; Li L; He Y; Dong X; Wang K; Lin H; Mao N; Liu L
    Oncologist; 2020 Jun; 25(6):e955-e963. PubMed ID: 32272498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy.
    Proulx-Rocray F; Routy B; Nassabein R; Belkaid W; Tran-Thanh D; Malo J; Tonneau M; Ouarzadi OE; Florescu M; Tehfe M; Blais N
    Cancer Treat Res Commun; 2023; 37():100767. PubMed ID: 37832364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma.
    Sun H; Liu SY; Zhou JY; Xu JT; Zhang HK; Yan HH; Huan JJ; Dai PP; Xu CR; Su J; Guan YF; Yi X; Yu RS; Zhong WZ; Wu YL
    EBioMedicine; 2020 Oct; 60():102990. PubMed ID: 32927274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated analysis of patients with KEAP1/NFE2L2/CUL3 mutations in lung adenocarcinomas.
    Jin X; Zheng Y; Chen Z; Wang F; Bi G; Li M; Liang J; Sui Q; Bian Y; Hu Z; Qiao Y; Xu S
    Cancer Med; 2021 Dec; 10(23):8673-8692. PubMed ID: 34617407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis.
    Li H; Yang L; Wang Y; Wang L; Chen G; Zhang L; Wang D
    BMC Bioinformatics; 2023 Apr; 24(1):155. PubMed ID: 37072703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Machine learning reveals two heterogeneous subtypes to assist immune therapy based on lipid metabolism in lung adenocarcinoma.
    Gu X; Wei S; Li Z; Xu H
    Front Immunol; 2022; 13():1022149. PubMed ID: 36238302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological, microenvironmental and genetic determinants of molecular subtypes in KEAP1/NRF2-mutant lung cancer.
    Cai MC; Chen M; Ma P; Wu J; Lu H; Zhang S; Liu J; Zhao X; Zhuang G; Yu Z; Fu Y
    Int J Cancer; 2019 Feb; 144(4):788-801. PubMed ID: 30411339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.